Skip to main
ELVN

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics Inc is strategically shifting its focus to the development of HER3-targeting antibody-drug conjugate EO-1022, which is expected to provide new revenue streams starting in 2031 while managing expenses effectively through workforce reductions. This move to streamline operations reflects a prudent approach to conserve funds in a challenging biotechnology sector, positioning the company to adapt better to market fluctuations. Despite adjustments to financial forecasts, including a reduction in revenue expectations from prior candidates, the emphasis on targeted therapies aligns with emerging market trends, potentially enhancing the company's long-term growth prospects.

Bears say

Enliven Therapeutics's recent announcement to discontinue the development of its Claudin 18.2-targeting ADC, EO-3021, due to lower-than-expected efficacy in Phase 1 studies raises concerns about the company's pipeline viability. Although the drug has been noted for its good tolerability and potential as a combination therapy, its low efficacy severely limits its attractiveness for further investment. This development, alongside adjustments to future financial projections, reinforces a negative outlook for Enliven Therapeutics's stock.

ELVN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELVN has a Strong Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.